Anticoagulation therapy may reportedly reduce tumor size in cancer patients with thrombosis; LMWHs (specific for factor Xa), such as dalteparin8and nadroparin,9significantly improve survival in patients with cancer compared with treatment without anticoagulant therapy. This evidence concerns the gene F10 and neoplasm.